Yecuris is a Portland, Oregon based corporation and was formed in April of 2007 to commercialize transgenic mouse technology that was developed in the lab of Dr. Markus Grompe at the Oregon Health and Sciences University. The FRG-KO (FRG) mice were originally developed to explore pathways for hereditary type I tyrosinemia, an often fatal pediatric disease. Based in part on support from the Grompe lab and the Yecuris™ mouse, medications have been developed to aid in the treatment of this disease.

More recently, the FRG model has been shown to be useful in a variety of areas including hepatocyte expansion, drug metabolism, infectious disease, toxicology, and safety applications. To date, the lack of a supply of robust primary hepatic materials and models has been an impediment to basic scientific research, timely delivery of drug candidates and cures, and the development of novel treatments for chronic and acute liver disease. The introduction of the Yecuris™ FRG mouse represents a significant advancement in the ability to provide researchers and clinicians with a dependable supply of these precious materials.

Our team of dedicated research and business professionals is committed to providing these materials to the market and developing next generation solutions that allow for improved utility and physiological relevance.

Contact Yecuris

For more information on Yecuris™ products and services, or partnerships that progress a shared mission, please contact us at [email protected]

Yecuris Corporation | P.O. Box 4645, Tualatin, OR 97062 | +1.503.352.4663

Founding Team

John Bial

Industry

BioPharmaceutical

Business Strategy

Scale

Funding Source

Angel & VC Funded

Exit Strategy

Acquisition

Founded

2007

Year Joined

2011

Chapter

Portland